Cortellini et al. specifically evaluated post-pembrolizumab monotherapy treatment in a stage IV NSCLC population with PD-L1 ≥ 50%, and 44% received further systemic therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.